Skip to main content

Table 2 CT-SS according to clinical data (n = 247)

From: Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19

  COVID-19 LDCT p value
Score
Mean ± SD
No Yes
Clinical data
 Sex (male/female) 5.1 ± 6.9 4.0 ± 6.0 0.247
 Symptoms 4.3 ± 6.4 4.5 ± 6.5 0.834
 Rhinitis 4.9 ± 6.7 3.9 ± 6.1 0.223
 Fever 4.1 ± 6.4 6.9 ± 6.2 0.002
 Anosmia 5.2 ± 7.3 3.7 ± 5.2 0.342
 Ageusia 4.6 ± 6.8 4.4 ± 6.0 0.805
 Dyspnea 3.5 ± 5.3 7.2 ± 8.3 < 0.001
 Chest pain 4.6 ± 6.7 4.0 ± 5.1 0.89
 Needed oxygen 4.0 ± 5.8 20.9 ± 7.9 < 0.001
 Desaturation 3.5 ± 5.4 13.2 ± 7.8 < 0.001
 Hospitalization 4.1 ± 6.0 15.3 ± 8.4 < 0.001
 Hypertension 3.9 ± 5.9 10.0 ± 8.1 < 0.001
 Diabetes 4.1 ± 6.2 12.0 ± 7.3 < 0.001
 Cancer status 4.3 ± 6.3 11.3 ± 7.0 0.003
 Cardiac disease 4.4 ± 6.4 9.1 ± 7.2 0.043
Demographics data
 Age 18–34 years 1.4 ± 2.8   < 0.001
 Age 35–44 years 3.2 ± 5.0   
 Age 45–54 years 5.2 ± 5.6   
 Age 55–64 years 8.5 ± 9.1   
 Age > 64 years 10.0 ± 6.9   
Delay between symptoms and LDCT
 0–3 days 1.4 ± 3.6   0.003
 4–7 days 4.4 ± 6.8   
 8–11 days 4.7 ± 6.2   
 > 11 days 7.1 ± 7.3   
  1. All significant results with a p < 0.05 have been highlighted in bold
  2. Distribution of the CT-SS according to symptoms across age and delay between symptoms and LDCT. The continuous variables are presented as the mean value ± DS
  3. COVID-19 coronavirus disease 2019, LDCT low-dose computed tomography, p value: Wilcoxon Mann–Whitney/Kruskal–Wallis test